P-228 SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies
نویسندگان
چکیده
منابع مشابه
Transoral Laser Microsurgery for Malignancies of the Upper Aerodigestive Tract
Transoral laser microsurgery (TLM) is an important option in the treatment plan for tumors of the oral cavity, oropharynx, larynx, and hypopharynx. For properly selected patients, TLM provides equivalent oncologic outcomes when compared to traditional therapies, while improving the functional aspects of postoperative speech, voice and swallowing.
متن کاملAn open-label phase I dose-finding study of APR-246 in hematological malignancies
Mutations in the TP53 tumor suppressor gene occur at different frequencies in a variety of human malignancies. TP53 encodes a DNA-binding transcription factor that induces cell growth arrest, senescence and cell death by apoptosis upon cellular stress, including oncogenic stress and DNA damage. In hematological malignancies TP53 mutations are common in relapsed/refractory disease and confers a ...
متن کاملAnalysis of Secondary Neck Nodes in Malignancies of Upper Aerodigestive Tract
Cervical lymphadenopathy, a common clinical problem, often presents as a diagnostic dilemma. It is imperative to establish a definite diagnosis as early in the course of evaluation as possible in order to institute a meaningful treatment. In view of rich lymphatic drainage, majority of patients with malignancies of upper aero digestive tract presents with regional dissemination of disease to ce...
متن کاملA phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
PURPOSE AQ4N is a novel prodrug that is selectively bioreduced to AQ4, a topoisomerase II inhibitor, in hypoxic tumor. This study assessed the maximum tolerated dose and pharmacokinetics of AQ4N when administered weekly in patients with advanced cancers. EXPERIMENTAL DESIGN AQ4N was administered as a 30-minute i.v. infusion on days 1, 8, and 15 of a 28-day cycle in eight dose cohorts ranging ...
متن کاملDenosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
BACKGROUND Giant-cell tumour (GCT) of bone is a primary osteolytic bone tumour with low metastatic potential and is associated with substantial skeletal morbidity. GCT is rich in osteoclast-like giant cells and contains mononuclear (stromal) cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. We investigated the potential therapeutic effect of denosumab, a fully hum...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2020
ISSN: 0923-7534
DOI: 10.1016/j.annonc.2020.04.310